Deferasirox (Exjade®)≥30 Mg/Kg/Day is effective in reducing iron burden in thalassemia major patients previously chelated with monotherapy or combination therapy / A. Taher, M.S. Elalfy, A. El Beshlawy, D. Zhou, L.L. Chan, C.K. Li, K.H. Lin, J.B. Porter, P. Sutcharitcharan, D. Habr, G. Domokos, B. Roubert, M.D. Cappellini. - In: BLOOD. - ISSN 0006-4971. - 114:22(2009 Nov), pp. 1556-1557. (Intervento presentato al 51. convegno ASH annual meeting tenutosi a New Orleans nel 2009).
Deferasirox (Exjade®)≥30 Mg/Kg/Day is effective in reducing iron burden in thalassemia major patients previously chelated with monotherapy or combination therapy
M.D. CappelliniUltimo
2009
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
